FDAnews
www.fdanews.com/articles/74974-adherex-initiates-two-additional-sites-for-phase-ii-trial-of-adh-1

ADHEREX INITIATES TWO ADDITIONAL SITES FOR PHASE II TRIAL OF ADH-1

August 3, 2005

Adherex Technologies, a biopharmaceutical company with a broad portfolio of oncology products under development, has initiated two additional sites for its Phase II clinical trial of ADH-1 (Exherin): Princess Margaret Hospital in Toronto and Jewish General Hospital in Montreal.

The study, which was launched May 2005 at the Ottawa Regional Cancer Centre, is designed to evaluate the antitumor activity and tolerability of repeated doses of ADH-1 on an every three-week schedule in patients whose tumors express the molecular target N-cadherin.